Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...

Merck estimates the project will create more than 500 full-time roles and about 4,000 construction jobs. CEO of Main Line ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

The pharmaceutical giant will invest $1 billion in a Delaware plant to manufacture Keytruda, as drugmakers ramp up U.S.

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...